ArticleSarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG2020
The incidence, comorbidity and mortality of sarcoidosis in Korea, 2008-2015: a nationwide population-based study.
Article in Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Incidence and prevalence of interstitial lung diseases worldwide: a systematic literature review.BMJ open respiratory research · 2023Pooled it
- Sarcoidosis with musculoskeletal manifestations: systematic review of non-pharmacological and pharmacological treatments.Rheumatology international · 2022Pooled it
- Sarcoidosis in hospitalised patients in Western Australia: A long-term study on prevalence, comorbidity and mortality.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2026Article
- Salivary Gland Sarcoidosis: Systematic Review of Case Reports and Case Series.Journal of clinical medicine · 2025Review
- Article
- Article
- Trends and Disparities Around Cardiovascular Mortality in Sarcoidosis: Does Big Data Have the Answers?Journal of the American Heart Association · 2024Article
- A nationwide cohort study on incidence and mortality associated with extracranial vascular malformations.Scientific reports · 2023Article
- [Sarcoidosis].Zeitschrift fur Rheumatologie · 2023Article
- Reasons for Hospitalization and All-Cause Mortality for Adults with Sarcoidosis.American journal of medicine open · 2023Article
- Rare manifestations of refractory extrapulmonary sarcoidosis.BMJ case reports · 2023Article
- Incidence of Retinal Artery Occlusion and Related Mortality in Korea, 2005 to 2018.JAMA network open · 2023Article
- Sex Differences in Temporal Trends in Hospitalizations and In-Hospital Mortality in Patients with Sarcoidosis in Spain from 2001 to 2020.Journal of clinical medicine · 2022Article
- HLA class II variants defined by next generation sequencing are associated with sarcoidosis in Korean patients.Scientific reports · 2022Article
- Diagnostic and Staging Value of Serum Angiotensin-Converting Enzyme in Sarcoidosis.Computational and mathematical methods in medicine · 2022Article
- Design and rationale of ProSar, the first Danish sarcoidosis registry.Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG · 2022Article
- Clinical characteristics and outcomes of Korean patients with sarcoidosis.Scientific reports · 2021Article
- Sarcoidosis mimicking metastases in an echinoderm microtubule-associated protein-like 4 anaplastic lymphoma kinase positive non-small-lung cancer patient: A case report.World journal of clinical cases · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFew national level, population-based studies are present on the epidemiology of sarcoidosis and it is unclear whether these patients have higher mortality than the general population. The objective of this study was to investigate the nationwide epidemiology, comorbidity and mortality in sarcoidosis in Korea. MATERIAL AND
methodsFor the period between 2008 to 2015, we used the national population-based database operated by Rare Intractable Disease registration program in which patients' diagnosis are based on uniform criteria. All sarcoidosis patients were identified and followed-up using the National Health Insurance database to determine their incidence, comorbidity, mortality, causes of death and standardised mortality ratio (SMR).
resultsDuring the study period, we identified 3,259 new sarcoidosis patients. The average annual incidence was 0.81 per 100,000. The annual mortality rate was 9.26 per 1,000 person-years. The mortality rate were significantly higher than those of the general population (SMR 1.91, 95% confidence interval 1.62-2.25). The major comorbidities of sarcoidosis patients were the diseases of the respiratory system (17.64%), heart (5.43%), eyes (4.27%) and cancer (2.3%). Mortality was higher in patients with lung involvement. Of the 84 deaths identified in this study from 2008-2013, the most common cause of death was cancer (41.7%), followed by respiratory disease (13.1%), sarcoidosis (13.1%) and heart disease (8.3%).
conclusionsWe reported a nationwide incidence of sarcoidosis as 0.81 per 100,000 in Korea. The mortality of sarcoidosis patients was higher compared to the general population and the major causes of death were cancer, respiratory disease and sarcoidosis. Sarcoidosis patients with comorbid diseases showed increased mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.